compound introduction
SB 242084 是一种具有选择性、竞争性和高亲和力的 (pKi=9.0) 的 5-HT2C 受体拮抗剂 (可透过血脑屏障)。SB 242084 能增加中脑腹侧被盖区 (VTA) 多巴胺能神经元的基础活性和伏隔核中多巴胺的释放。SB 242084 还可通过 5-HT2A 受体增加线粒体基因的表达和氧化代谢。SB 242084 在焦虑、抑郁和精神分裂症的阴性症状以及急性器官损伤方面具有较好的研究潜力。 SB 242084 is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage.
